FDA Warns Again Of Rare Cancer Associated With TNF Blockers
Executive Summary
FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.
You may also be interested in...
FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma
Manufacturers must conduct in-depth follow-up of reported malignancies in children and young adult patients and submit them to FDA within 15 days of learning about the cases.
FDA Skeptical Of Maintenance Claims For Centacor's Remicade In Pediatric Ulcerative Colitis
Agency accepts 8-week efficacy, but says long-term data is sparse for the tumor necrosis factor inhibitor, which goes before the Gastrointestinal Drugs Advisory Committee July 21.
Remicade Pediatric Indication Likely Faces Safety Scrutiny At Advisory Committee
Risks of cancer and fungal infections are likely to grab a great deal of attention from the Gastrointestinal Drugs Advisory Committee when it reviews Centocor Ortho Biotech's Remicade (infliximab) for children July 21.